ChromaDex and the Scripps Research Institute collaborate
ChromaDex Corporation (CDXC) (Irvine, California, USA) has announced that it has collaborated with the Scripps Centre for Metabolomics (La Jolla, California, USA) to generate tandem mass spectrometry data for compounds from the ChromaDex natural products and phytochemical catalogue.
ChromaDex Corporation (CDXC) (Irvine, California, USA) has announced that it has collaborated with the Scripps Centre for Metabolomics (La Jolla, California, USA) to generate tandem mass spectrometry data for compounds from the ChromaDex natural products and phytochemical catalogue. There is currently limited information for natural products in the database. By expanding the population of data, it will increase the knowledge base for researchers to screen potential compounds for use in areas of clinical interest.
The Scripps METLIN Metabolite Database is a repository of metabolite information that includes tandem mass spectrometry data for over 55,000 compounds. It is a public, web-based database designed for the archiving, visualization and analysis of metabolite data.
Gary Siuzdak, PhD, senior director, Centre for Metabolomics and Mass Spectrometry Scripps Research Institute, commented, “We are very excited about expanding the METLIN metabolite database with the ChromaDex phytochemicals. METLIN is currently the largest repository of metabolite tandem mass spectrometry data. The importance in the ChromaDex/METLIN partnership is that it will facilitate metabolomics experiments around the world.”
Frank Jaksch, founder and CSO for ChromaDex, said, “Collaborating with Scripps Research Institute with our natural product libraries will further advance small molecule profiling to increase demand for natural product libraries through the ease of the internet to assist in finding candidate compounds for research and development.”
For more information please visit ref="http://www.chromadex.com">www.chromadex.com
Free Poster: NDSRI Risk Assessment and Trace-Level Analysis of N-Nitrosamines
April 25th 2025With increasing concern over genotoxic nitrosamine contaminants, regulatory bodies like the FDA and EMA have introduced strict guidelines following several high-profile drug recalls. This poster showcases a case study where LGC and Waters developed a UPLC/MS/MS method for quantifying trace levels of N-nitroso-sertraline in sertraline using Waters mass spectrometry and LGC reference standards.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
Using the Carcinogenic Potency Categorisation Approach (CPCA) to Classify N-nitrosamine Impurities
April 25th 2025Learn how to manage nitrosamine impurities in pharmaceuticals with our free infographic. Discover how the CPCA approach establishes acceptable intake limits and guides the selection of NDSRI reference samples. Stay compliant and ensure safety with our ISO-accredited standards.
